Yes, apixaban 10 mg twice daily can be used to treat pulmonary embolism after completing 10 days of therapeutic-dose enoxaparin.
You can transition directly from enoxaparin to apixaban 10 mg twice daily without any additional bridging or overlap, starting apixaban at the time of the next scheduled enoxaparin dose. This approach is explicitly supported by FDA labeling and multiple international guidelines 1.
Dosing Algorithm for PE Treatment with Apixaban
Initial Phase (Days 1-7 of apixaban therapy):
- Apixaban 10 mg orally twice daily for 7 days 1
- Since your patient has already received 10 days of therapeutic enoxaparin, they would start directly with this 10 mg twice-daily regimen
Maintenance Phase (After 7 days):
- Reduce to apixaban 5 mg orally twice daily 1
- Continue for at least 3 months total anticoagulation duration 2
Transition Protocol:
When switching from enoxaparin to apixaban: Discontinue enoxaparin and begin apixaban at the usual time of the next scheduled enoxaparin dose 1. No overlap or bridging is required.
Evidence Supporting This Approach
The AMPLIFY trial directly validated this strategy, demonstrating that apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) was noninferior to enoxaparin/warfarin for preventing recurrent VTE (2.3% vs 2.7%) with significantly less major bleeding (0.6% vs 1.8%, P<0.001) 3, 4. The 2016 CHEST guidelines and 2021 ACC consensus both explicitly endorse this dosing regimen 4, 5, 4.
Important Clinical Considerations
Dose Adjustments:
- If combined P-gp and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) are present: reduce apixaban dose by 50% 1
- Renal impairment: Avoid if CrCl <15 mL/min; use caution if CrCl 15-25 mL/min 6
- Hepatic impairment: Avoid if transaminases >2× ULN or bilirubin >1.5× ULN 6
Cancer-Associated PE:
If this PE is cancer-related, LMWH (continuing enoxaparin) is preferred over apixaban for the first 3 months 4. The guidelines suggest LMWH over DOACs (Grade 2C) in cancer-associated thrombosis due to limited data in this population 4.
Duration of Therapy:
- Minimum 3 months for all PE patients 2
- Provoked by major transient risk factor: Stop at 3 months 2
- Unprovoked or persistent risk factor: Consider extended therapy with reduced-dose apixaban 2.5 mg twice daily after completing 6 months of full-dose treatment 2, 1
Common Pitfalls to Avoid
Do not overlap enoxaparin and apixaban - unlike warfarin transitions, DOACs like apixaban do not require bridging 1
Do not use the 2.5 mg twice-daily dose initially - this reduced dose is only for extended secondary prevention after at least 6 months of treatment, not for acute PE treatment 1
Do not forget the 7-day loading phase - the higher 10 mg twice-daily dose for the first week is critical for acute treatment efficacy 3
Reassess at 3 months - all patients require evaluation for extended-phase anticoagulation at this timepoint 2
The pharmacokinetic interaction between enoxaparin and apixaban is minimal and additive rather than synergistic, with no effect on apixaban absorption 7. The modest increase in anti-Xa activity when transitioning is further mitigated by timing the switch at the next scheduled dose interval 7.